Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Allan Kaspar"'
Autor:
Janice M. Reichert, Allan Kaspar
Publikováno v:
Drug Discovery Today. 18:807-817
The notable expansion of peptide therapeutics development in the late 1990s and the 2000s led to an unprecedented number of marketing approvals in 2012 and has provided a robust pipeline that should deliver numerous approvals during the remainder of
Autor:
Mark Horn, Ruth Muchekehu, Joselyn Del Rosario, Steven Pirie-Shepherd, Allan Kaspar, Dingguo Liu, Venkata Doppalapudi, Trina Osothprarop, Julia Coronella, Haim Moskowitz, Michael Bacica, Lioudmila Campbell, Anouk Dirksen
Publikováno v:
Translational oncology. 6(5)
Poor drug delivery and penetration of antibody-mediated therapies pose significant obstacles to effective treatment of solid tumors. This study explored the role of pharmacokinetics, valency, and molecular weight in maximizing drug delivery. Biodistr
Autor:
Matthew J. Rames, Lei Zhang, Liqing Huang, Gang Ren, Huimin Tong, Allan Kaspar, Gary Woodnutt
Publikováno v:
Scientific Reports
Scientific reports, vol 3, iss 1
Tong, H; Zhang, L; Kaspar, A; Rames, MJ; Huang, L; Woodnutt, G; et al.(2013). Peptide-conjugation induced conformational changes in human IgG1 observed by optimized negative-staining and individual-particle electron tomography. Scientific Reports, 3. doi: 10.1038/srep01089. Lawrence Berkeley National Laboratory: Retrieved from: http://www.escholarship.org/uc/item/6pv4d8cg
Scientific reports, vol 3, iss 1
Tong, H; Zhang, L; Kaspar, A; Rames, MJ; Huang, L; Woodnutt, G; et al.(2013). Peptide-conjugation induced conformational changes in human IgG1 observed by optimized negative-staining and individual-particle electron tomography. Scientific Reports, 3. doi: 10.1038/srep01089. Lawrence Berkeley National Laboratory: Retrieved from: http://www.escholarship.org/uc/item/6pv4d8cg
Peptides show much promise as potent and selective drug candidates. Fusing peptides to a scaffold monoclonal antibody produces a conjugated antibody which has the advantages of peptide activity yet also has the pharmacokinetics determined by the scaf
Autor:
Abhijit Bhat, Bin Liu, Joel Desharnais, Joselyn Del Rosario, Gary Woodnutt, Oscar Betancourt, Steven Pirie-Shepherd, Lingna Li, Rodney W. Lappe, Nancy Levin, Allan Kaspar, Dingguo Liu, Janet Do
Publikováno v:
Cancer Research. 71:LB-396
FGFR4 is the receptor for FGF19. Published data has shown FGF19 transgenic animals develop hepatocellular carcinoma (HCC), suggesting that the FGFR4:FGF19 axis may play a role in HCC. FGFR4 upregulation has been shown to be a negative prognostic indi
Autor:
Mayuko Omori, Carol Meschter, Negar Ghahramani, Paola Lanza, Daniel Brigham, Allan Kaspar, Salvatore Albani, Rosario Billetta
Publikováno v:
Clinical Immunology. 119:S118